A randomized phase II trial of ridaforolimus (AP23573; MK-8669) compared to progestin or chemotherapy in female adult patients with advanced endometrial carcinoma
- Registry ID
- EUCTR2008-000634-53
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE2
- Sponsor
- Merck Sharp & Dohme Corp.,
- Start date
- 2008-10-09
- Completion date
- 2012-07-09
- Last update
- 2026-08-16
Conditions
- carcinoma avanzado
- advanced endometrial carcinoma
Summary
To compare progression-free survival (PFS) of patients with advanced, recurrent or metastatic endometrial cancer who have received one, but not more than two prior lines of chemotherapy either as adjuvant therapy or treatment for advanced disease as defined in Table 11.1.4-1. and then treated with ridaforolimus or the investigator's choice of progestin or chemotherapy.
Locations
- , , UK
- , , Italy
- , , Czechia
- , , Spain
- , , Germany
- , , France
View on source registry